Let’s focus on the main game for a moment.
There have now been 15 comments submitted for consideration by the ODAC committee on Thursday.
The latest is from a Dr Tom Shannon, definitely very supportive of MSB’s application.
Dr Shannon is “excited by the prospect of a new type of therapy targeting inflammation, without the side effects of steroids and NSAIDS or even chemotherapeutic / disease modifying agents”.
He says “I was concerned to see details today of advice that may restrict access … If safety and efficacy can be achieved, even with the issues of QA around cell lines, then surely those treatments are valid.”
Definitely worth a read.
https://beta.regulations.gov/document/FDA-2020-N-1539-0037
Herro.
Let’s focus on the main game for a moment. There have now been...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
-0.050(3.31%) |
Mkt cap ! $1.681B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.50 | $1.45 | $6.543M | 4.463M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 10680 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 65748 | 20 |
View Market Depth
| Last trade - 14.45pm 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |